Risk of Primary Non Breast Cancer After Female Breast Cancer by Age at Diagnosis
|
|
- Cuthbert Dennis
- 5 years ago
- Views:
Transcription
1 Research Article Cancer Epidemiology, Biomarkers & Prevention Risk of Primary Non Breast Cancer After Female Breast Cancer by Age at Diagnosis Lene Mellemkjær 1, Jane Christensen 1, Kirsten Frederiksen 1, Eero Pukkala 3, Elisabete Weiderpass 4,5,6, Freddie Bray 5,7, Søren Friis 1, Michael Andersson 2, and Jørgen H. Olsen 1 Abstract Background: Women diagnosed with breast cancer at young age have been shown to be at higher risk of developing a new primary cancer than women diagnosed at older ages, but little is known about whether adjustment for calendar year of breast cancer diagnosis, length of follow-up, and/or breast cancer treatment alters the risk pattern by age. Methods: We identified 304,703 women diagnosed with breast cancer during 1943 to 2006 in the Cancer Registries of Denmark, Norway, and Finland. Relative risks () of subsequent non breast cancer by age at cancer diagnosis were calculated using Poisson regression models adjusted for country, calendar period, length of follow-up, and treatment. Excess absolute risks (EAR) were also calculated. Results: The for all cancer sites except breast cancer decreased with increasing age both with and without adjustments. The and the EAR differed for each age at diagnosis category until the women reached their late 70s. Many specific cancer forms contributed to the overall risk pattern by age with endometrial cancer as 1 exception. Conclusions: The age at breast cancer diagnosis is an essential risk factor for being diagnosed with a new primary non breast cancer and the level of risk for specific ages at diagnosis may hold for many years after the diagnosis. Occurrence of endometrial cancer after breast cancer seems to follow a distinct age pattern different from that seen for most other cancer types. Impact: Future studies should aim at exploring the underlying explanations for the age-related findings. Cancer Epidemiol Biomarkers Prev; 20(8); Ó2011 AACR. Introduction Authors' Affiliations: 1 Institute of Cancer Epidemiology, Danish Cancer Society; 2 Oncology Clinic, Finsen Center, National University Hospital, Copenhagen, Denmark; 3 Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research; 4 Samfundet Folkh alsan, Helsinki, Finland; 5 Cancer Registry of Norway, Oslo, Norway; 6 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 7 Cancer Information Section, IARC, Lyon, France Corresponding Author: Lene Mellemkjær, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboule-varden 49, DK-2100 Copenhagen, Denmark. Phone: ; Fax: ; lene@cancer.dk doi: / EPI Ó2011 American Association for Cancer Research. The high incidence of breast cancer in developed countries (1) combined with the favorable survival for the disease (2) makes breast cancer survivorship issues an important topic. Female survivors from breast cancer have been shown to be at increased risk of being diagnosed with additional primary cancers with risks consistently reported as higher among women diagnosed at younger ages relative to older ages (3 15). Younger breast cancer patients more often have unfavorable tumor characteristics and are more frequently treated with chemotherapy (16). Thus, age-related differences in the risk of second cancers may be partly explained by an excess of treatment-induced cancer among the youngest patients. Since it is possible to follow young patients over extensive periods of time, young patients tend to be more frequent among those with long-term follow-up and among those diagnosed in earlier calendar periods. Long-term follow-up (3, 8, 9) and early calendar years (8, 9) have been found to be associated with a higher risk of second non breast cancer, but previous large-scale cancer registry based studies have generally reported crude risks for second cancer by age, i.e., risks that were not adjusted for length of follow-up and calendar year. We aimed at testing the hypothesis that the relative risk () of subsequent non breast cancer according to age at breast cancer diagnosis is dependent on length of followup and/or calendar period of breast cancer diagnosis by using multivariate models applied to a cohort of approximately 300,000 women with breast cancer from Denmark, Finland, and Norway. We also investigated how much of the age effect may be explained by age-related differences in treatment by adjusting the models for treatment. In addition, we assessed how the relative and the absolute 1784 Cancer Epidemiol Biomarkers Prev; 20(8) August 2011
2 Cancer After Breast Cancer risks of a subsequent cancer throughout life depend on the age at breast cancer diagnosis. Material and Methods Women with breast cancer at all stages at ages above 20 years were identified in the population-based Cancer Registries in Denmark ( ; refs. 17, 18), Finland ( ; ref. 19), and Norway ( ; ref. 20). These Nordic Registries are national and are based on reports of cancer from multiple sources which increase both the completeness and the quality of the data. In addition to malignant neoplasms, the registries also include papillomas of the urinary tract and histologically benign tumors of the central nervous system and meninges, and these tumors were included in the analyses. In situ cancers such as carcinoma in situ of the cervix are also reported to the registries but were not included in the analyses. There are different registration procedures for non-melanoma skin cancer and contralateral breast cancer in the 3 registries, and therefore, breast cancer patients were not followed up for these types of cancer. From each Cancer Registry, the following variables were collected: date of birth, vital status, date of breast cancer diagnosis, and initial treatment of breast cancer in 3 broad categories (radiotherapy, chemotherapy, and hormonal therapy). Initial treatment was defined as treatment initiated within 4 months of the date of diagnosis. Information on histology was not obtained from the registries, because it has not been registered for the entire study period in Denmark and Norway. Extent of tumor at time of diagnosis was also not obtained. Information on all primary cancers (except contralateral breast cancer and non-melanoma skin cancer) occurring among women in the breast cancer cohort was obtained by a search through each of cancer registry files. Those diagnosed with cancer (other than non-melanoma skin cancer) prior to a breast cancer diagnosis were excluded from the study. For all malignancies diagnosed after a breast cancer diagnosis, the following variables were obtained from the registries: date of diagnosis and type of cancer [International Classification of Diseases, 7th revision (ICD-7) or 10th revision (ICD-10)]. The subsequent cancers were grouped according to possibly causative factors into: * radiotherapy-related: salivary glands, esophagus, lung, pleura, bone, connective tissue, and thyroid gland (9); * chemotherapy-related: leukemia (21); * tamoxifen-related: endometrial cancer (22); * BRCA-gene related: ovarian cancer (23) * alcohol-related: mouth, pharynx, liver, and larynx (24); and * overweight/obesity-related: colorectum, gallbladder and bile ducts, pancreas, and kidney (25, 26). Several cancer types are likely to be associated with more than 1 of the aforementioned risk factors, but we did not allow overlap between the groups. Cancer sites belonging to treatment-related sites and other groups (e.g., esophageal and endometrial cancer) were included among the treatment-related sites. Colorectal cancer which is associated with both overweight/obesity and alcohol was placed in the overweight/obesity group, because the evidence for this association is stronger than that for alcohol (25). The follow-up period started at the first day of the month following the month when the breast cancer was diagnosed and continued until date of death, emigration, or end of study [December 31, 2006 (Denmark and Finland) or December 31, 2007 (Norway)]. Statistical analysis Person-years and observed cancers after the breast cancer diagnosis were assigned to strata defined by 5- year intervals of attained age and calendar year. For each country, cancer incidence rates among the general population in corresponding age and calendar year intervals were multiplied with the strata-specific accumulated person-years to estimate the number of expected cancer cases. Crude estimates for subsequent cancer were calculated as standardized incidence ratios (SIR) with 95% CIs, assuming Poisson distributed number of observed cancers. Multivariate log linear Poisson regression models were used to estimate s of subsequent cancer according to age at breast cancer diagnosis (<40, 40 49,...,70þ years) with adjustment for calendar period of breast cancer diagnosis ( ,..., ), length of follow-up (<1, 1 4, 5 9, and 10þ years), radiation therapy (yes, no, and unknown), chemotherapy (yes, no, and unknown), and hormonal therapy (yes, no, and unknown). Competing risks have been considered by comparison of cancer rates with censoring of the patients when they die or emigrate. To investigate whether risk by age at breast cancer diagnosis was similar throughout the study period, we tested the interaction between age at breast cancer diagnosis entered as a continuous variable in 1-year age groups and the calendar periods defined previous. The GENMOD procedure in SAS version 9.1 was used for the Poisson regression analyses (SAS Institute). Finally, we computed the excess absolute risk (EAR) as the observed minus the expected number of subsequent cancer cases divided by the accumulated person-years. Results We identified a total of 304,703 women with breast cancer as the first primary cancer. The number of patients in each country is shown in Table 1 along with the distribution of patients by age at breast cancer diagnosis, calendar period of diagnosis, and type of breast cancer treatment. The women were followed for an average of 8.8 years (>0 62 years). Among 21,502 women with a new Cancer Epidemiol Biomarkers Prev; 20(8) August
3 Mellemkjær et al. Table 1. Characteristics of breast cancer patients from Denmark, Finland, and Norway Denmark Finland Norway No. of patients (%) No. of patients (%) No. of patients (%) All patients 133,061 (100) 95,747 (100) 75,895 (100), y <40 7,605 (6) 5,530 (6) 4,235 (6) ,293 (18) 18,848 (20) 13,327 (18) ,391 (24) 24,848 (26) 16,360 (22) ,852 (24) 21,590 (23) 17,425 (23) 70þ 37,920 (28) 24,931 (26) 24,548 (32) Calendar period for breast cancer a 9,612 (7) ( ) ( ) ,175 (9) 6,523 (7) 8,877 (12) ,464 (12) 9,477 (10) 11,341 (15) ,558 (16) 14,304 (15) 14,356 (19) ,271 (20) 21,640 (23) 17,039 (22) ,687 (25) 30,048 (31) 21,783 (29) b 14,294 (11) 13,755 (14) 2,499 (3) Type of breast cancer treatment Radiation: Yes 55,764 (42) 44,396 (46) 29,359 (39) No 65,995 (50) 46,636 (49) 28,109 (37) Unknown 11,302 (8) 4,715 (5) 18,427 (24) Chemotherapy: Yes 12,926 (10) 11,010 (12) 12,510 (16) No 108,833 (82) 79,474 (83) 30,891 (41) Unknown 11,302 (8) 5,263 (5) 32,494 (43) Hormonal therapy: Yes 14,232 (11) 7,404 (8) 17,335 (23) No 107,527 (81) 82,478 (86) 27,443 (36) Unknown 11,302 (8) 5,865 (6) 31,117 (41) a Only patients from Denmark. b Patients from Norway only through malignancy during follow-up, 19,833 (92%) had 1 malignancy, 1,544 (7%) had 2, 117 (%) had 3, and 8 (0.04%) had 4 malignancies. Thus, a total of 23,304 new primary cancers (excluding contralateral breast and non-melanoma skin cancer) were diagnosed during follow-up, whereas 20,330 cancers were expected resulting in an overall SIR of 1.15 (95% CI ¼ ) and with SIRs of 1.30 (95% CI ¼ ) less than 1 year after breast cancer diagnosis, 5 (95% CI ¼ 2 7) 1 to 4 years after diagnosis, 1.17 (95% CI ¼ ) 5 to 9 years after diagnosis, and 1.17 (95% CI ¼ ) 10 or more years after diagnosis. In the crude SIR analysis, the risk of developing a new primary cancer clearly decreased with increasing age at breast cancer diagnosis, and this pattern was largely unchanged after adjustment for calendar period of breast cancer diagnosis, length of follow-up, and country of residence (Table 2). Comparable risk patterns by age were obtained when data from each of the countries were analyzed separately and when starting follow-up 1 year after the breast cancer diagnosis (data not shown). The decreasing linear effect of age at breast cancer diagnosis was similar for all calendar periods (P ¼ 0.32; data not shown). The association between breast cancer and subsequent cancers by age at breast cancer diagnosis was largely unchanged after further adjustment for radiotherapy, chemotherapy, and hormonal therapy (Table 2). Given the evidence of a strong association between young age at breast cancer diagnosis and risk of ovarian cancer, we omitted this cancer and still found a clear decrease in risk of a subsequent primary cancer with increasing age at breast cancer diagnosis. We found an inverse relationship between EAR and age at diagnosis, with EAR decreasing from 252 per 100,000 person-years among patients below age 40 years at breast cancer diagnosis to 183 per 100,000 person-years among patients aged 40 to 49, 130 per 100,000 personyears among patients aged 50 to 59, 90 per 100,000 person-years among patients aged 60 to 69, and 67 per 100,000 person-years among patients above age 70 years at breast cancer diagnosis. The of subsequent cancer among patients diagnosed with breast cancer before age 40 years decreased 1786 Cancer Epidemiol Biomarkers Prev; 20(8) August 2011 Cancer Epidemiology, Biomarkers & Prevention
4 Cancer After Breast Cancer Table 2. SIRs and s for all subsequent cancer sites combined (except breast and nonmelanoma skin cancer) among breast cancer patients from Denmark, Finland, and Norway according to age at breast cancer diagnosis Age at breast cancer, y No. of subsequent cancer Personyears Crude All sites adjusted a,b All sites further adjusted c,d All sites except ovarian cancer adjusted a,b SIR 95% CI 95% CI 95% CI 95% CI <40 1, , , , , , , , þ 5, , a Adjusted for calendar period, length of follow-up, and country. b Estimates presented for the following reference levels: calendar period , length of follow-up 5 9 years, and country Denmark. c Adjusted for calendar period, length of follow-up, country, radiation therapy, chemotherapy, and hormonal therapy. d Estimates presented for the following reference levels: calendar period , length of follow-up 5 9 years, country Denmark, no radiation therapy, no chemotherapy, and no hormonal therapy. by attained age until around age 50 years and was rather constant by increasing attained ages from around 50 to 75 years (Fig. 1A). The same pattern was seen for those diagnosed at older ages with the curve for each subsequent age group at a lower level. Each of the age groups also had their own level of EAR by attained age being higher, the younger the patients were at breast cancer diagnosis (Fig. 1B). The EAR tended to increase by attained ages from around 50 to 75 years for all age groups with the highest absolute risks found when patients were in their 60s and early 70s. We found significantly increased SIRs for the groups of possibly treatment-related cancer sites, BRCA gene-, and overweight/obesity-related cancer sites (Table 3). A B SIR EAR < Attained age, y 200 < Attained age, y Age at BC, y < Figure 1. A, SIR of subsequent non breast cancer after breast cancer by attained age for different ages at breast cancer diagnosis. B, EAR, number of excess subsequent non breast cancers per 100,000 person-years after breast cancer by attained age for different ages at breast cancer diagnosis (Age at BC, age at breast cancer diagnosis). Cancer Epidemiol Biomarkers Prev; 20(8) August
5 Mellemkjær et al. Table 3. SIRs for all ages and adjusted s according to age at breast cancer diagnosis for specific cancer sites among breast cancer patients from Denmark, Finland, and Norway Cancer sites grouped according to possible underlying cause All ages crude diagnosis adjusted a,b,y P trend Obs SIR EAR c < þ Radiation-related sites 3, d d 1.58 d 1.17 d 1.11 d 0.90 < Salivary glands Esophagus d d 2.27 d 1.73 d 1.66 d Lung 2, d d 1.56 d < Pleura d d 3.90 d Bone d d Connective tissue d d 2.37 d 1.79 d 0 d Thyroid gland d d < Chemotherapy-related site Leukemia d d 1.35 d < Tamoxifen-related site Endometrium 2, d d 1.21 d 1.28 d 1.59 d 1.64 d < BRCA-gene related site Ovary 1, d d 1.99 d 1.38 d < Alcohol-related sites e Mouth Pharynx Liver d d Larynx Overweight/obesity related sites f 6, d d 1.16 d 1.11 d < Colorectum 4, d d d < Gall bladder and biliary tract d Pancreas 1,101 6 d d Kidney d d d Other specified sites Lip d Tongue Stomach 1, d d 2.40 d 1.98 d 1.40 d 1.11 < Small intestine d Digestive tract NOS d Nose and middle ear Mediastinum Melanoma d Cervix d d 0.60 d 0.61 d 0.65 d 0.12 Other female organs d Urinary bladder d d 0.76 d < Brain and CNS d Eye d Adrenal gland Lymphoma d Multiple myeloma Metastases and unspecified sites d d 5.24 d 3.35 d 4 d 1.54 d < a Adjusted for calendar period, length of follow-up, and country. b Estimates presented for the following reference levels: calendar period , length of follow-up 5 9 years, and country Denmark. c EAR; number of excess cases of subsequent cancer per 100,000 person-years. d P < e Esophagus and colorectum not included due to overlap with other groups. f Esofagus and endometrium not included due to overlap with other groups Cancer Epidemiol Biomarkers Prev; 20(8) August 2011 Cancer Epidemiology, Biomarkers & Prevention
6 Cancer After Breast Cancer The adjusted s decreased by increasing age at first breast cancer, though the slope of the decrease varied (Fig. 2A, B, D, and F). For the tamoxifen-related site, endometrial cancer, the risk only decreased for patients less than 50 years at diagnosis; at older ages at diagnosis, the risk increased by increasing age at breast cancer (Fig. 2C). Among other specified sites, the risk of a subsequent cancer decreased significantly by increasing age at diagnosis for stomach cancer, melanoma, and urinary bladder cancer and nonsignificantly for several other specified cancer sites (Table 3). These age-specific results were adjusted for calendar year, length of follow-up, and country; after further adjustment for treatment, the results for all 3 groups of possibly treatment-related cancer sites changed only slightly (data not shown). Exclusion of the first year of follow-up had no major impact on the riskpatternsbyageseeninfigure2atof(datanot shown). Discussion diagnosis remains a key determinant for the of developing a new primary non breast cancer when calendar year of breast cancer diagnosis, length of follow-up, and breast cancer treatment have been taken into consideration. The age-specific variation in seems to persist throughout life. The risk pattern by age was observed during the last 5 decades, despite major changes in treatment and in prevalence of risk factors within the populations. A decrease in risk by increasing age at breast cancer diagnosis was seen for the majority of cancer sites -1 exception was endometrial cancer for which the risk increased by increments of ages above 50 years at diagnosis. Our finding of a clear inverse trend in the SIRs for subsequent non breast cancer by age at first breast cancer diagnosis is consistent with recent cancer registry-based studies from the United States and the Netherlands (3, 4). A Salivary glands, esophagus, lung, pleura, bone connective tissue, and thyroid gland (possibly radiation-related sites) B Leukemia (chemotherapy-related site) Figure 2. s and 95% CIs for subsequent cancer sites categorized according to possible underlying cause (A) to (F) by age at breast cancer adjusted for country, calendar period, and length of follow-up. Estimates presented for the following reference levels: calendar period 1993 to 2002, length of follow-up 5 to 9 years, and country Denmark. C E Endometrium (tamoxifen-related site) Mouth, pharynx, liver, and larynx (alcohol-related sites) D F Ovary (BRCA gene-related site) Colorectum, gallbladder and tract, pancreas, and kidney (overweight/obesity-related sites) Cancer Epidemiol Biomarkers Prev; 20(8) August
7 Mellemkjær et al. We adjusted the risk estimates by age at breast cancer diagnosis for length of follow-up and calendar period to separate the collinear effects of age, length of follow-up, and calendar period. The age effects were quite similar with and without such adjustment, suggesting that the age effect is rather independent of length of follow-up and calendar year. Also, initial treatment for breast cancer had little impact on the age effects in the study population. To our knowledge, only 1 study presented adjusted risk estimates; in this study that included a subset of the Danish breast cancer patients in the present study, age effects were adjusted for length of follow-up and treatment, and the risk pattern by age was similar to ours for the 3 cancer sites shown (11). We found a larger absolute excess of cancer cases among women who were young at diagnosis than women who were older at diagnosis, and therefore the decreasing is unlikely to be merely a consequence of low cancer rates in the young background population. Thus, age at breast cancer diagnosis seems to be a good indicator for susceptibility to develop a new cancer, and this level of risk seems to remain different for each age category throughout most of a lifetime. For most of the cancer sites or groups of cancer sites, we found a decrease in risk by increasing age at breast cancer though the magnitude of decrease varied. We found a steep decrease in risk for ovarian cancer by age at breast cancer in accordance with earlier studies (3 5); deleterious mutations in the BRCA1 and BRCA2 genes predisposing to breast cancer and ovarian cancer are likely to be the underlying explanation for this observation (27). Breast cancer patients treated with chemotherapy have previously been found to have an excess risk of leukemia (4, 28, 29). A prior study classified cancer of the esophagus, lung, pleura, thyroid, bone, connective tissue, and salivary glands as potentially radiotherapy-related sites based on a review of the literature (9). We found a moderate decreasing trend in risk by age at breast cancer diagnosis for these cancer sites combined and for leukemia. A similar pattern was seen in the Surveillance Epidemiology and End Results (SEER) data from the United States (3). Our results changed only slightly following adjustment for treatment, indicating that the pattern could not be caused by a higher frequency of treatment among young patients. However, the moderate decrease by age at diagnosis of breast cancer may possibly be a consequence of a higher sensitivity toward radiation or chemotherapy at younger ages at exposure, as suggested by results on radiotherapy treated 5-year survivors from SEER registries (30), and in parallel to what has been observed for radiotherapy and contralateral breast cancer (31, 32). We found a weak U-shaped relationship between age at breast cancer and risk of endometrial cancer consistent with some previous studies (3, 4), whereas 1 study reported a clear increasing trend by increasing age (5). The increase in risk of endometrial cancer by age confined to older age groups is in contrast to the findings for most cancer sites, where risk decreased by age throughout the age spectrum or no trend by age was seen. The reason for this atypical excess at older ages is not clear, but different risk factors could be responsible for the excess seen in youth and later in life, respectively. In addition to treatment with tamoxifen that is associated with an increased risk of endometrial cancer (22), shared etiology related to hormonal exposure such as reproductive history and/or obesity (25) may play a role. Even though alcohol intake is a risk factor for breast cancer (25), we found s below 1 for alcohol-related cancer sites for all age groups except age at diagnosis less than 40 years. The effect of alcohol may to some extent be underestimated due to possible underreporting of liver cancer as primary cancer, because the liver is a common metastatic site for breast cancer. A weak decreasing trend in risk of overweight/obesity-related sites by age at diagnosis of breast cancer was seen with no significantly increased risks for ages above 59 years at breast cancer diagnosis. Since increased body fatness is positively associated with postmenopausal breast cancer but negatively associated with premenopausal breast cancer (25), the observed pattern is not consistent with excess body fatness as the underlying explanation. The finding of a bidirectional association between breast cancer and malignant melanoma in combination with reports of a higher risk of melanomas among BRCA mutation carriers and a higher risk of breast cancers among carriers of mutations in the melanoma susceptibility gene, CDKN2A, has led to the suggestion of a genetic link between the 2 diseases (33). However, although we found a significant trend by age, the lack of a markedly pronounced excess of melanomas among the youngest breast cancer patients in our and other studies (3, 4) does not favor this explanation. Common risk factors for early-onset breast cancer and malignant melanoma may also explain the observation. Our study included breast cancer patients from 3 national and population-based Nordic Cancer Registries with follow-up for new primary cancers up to 60 years after initial breast cancer diagnosis. By use of Poisson regression models, we assessed stratified by age at breast cancer diagnosis and adjusted for calendar period and length of follow-up. We restricted the study to Nordic Cancer Registries that include data on treatment to enable adjustment for treatment effects; however, it should be noted that some misclassification may occur because only initial treatment is registered and that type of treatment was missing for approximately 15% of patients, so we may not have fully adjusted for the treatment variables. Also, we did not have information on genetic, lifestyle, and reproductive risk factors for breast cancer. We restricted the study population to first primary breast cancer cases to avoid interference from treatment of another cancer preceding the breast cancer. Contralateral breast cancers were not included as an outcome, but follow-up continued independently of whether a contralateral breast cancer or a non breast 1790 Cancer Epidemiol Biomarkers Prev; 20(8) August 2011 Cancer Epidemiology, Biomarkers & Prevention
8 Cancer After Breast Cancer cancer occurred, because the background cancer incidence rates were multiple cancer rates. Any treatment of a second cancer may affect the risk of a third cancer; however, a relatively small part of breast cancer patients have more than 1 subsequent cancer diagnosis (3), so this is unlikely to have had a substantial impact on our results. Possible misclassification of metastases as new primary cancer and more intense screening for new cancers may lead to overestimation of risk for new primaries, although screening, e.g., for cervical cancer, could have the opposite effect as precancerous lesions are identified. The findings of our large-scale study underline the importance of age at diagnosis of the first primary breast cancer as a predictor of developing a new primary non breast cancer independently of the calendar period of diagnosis of the breast cancer and the time passed since diagnosis. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. Acknowledgments We thank A. Bautz at the Institute of Cancer Epidemiology, Danish Cancer Society, and S. Larønningen at the Cancer Registry of Norway for computer assistance. Grant Support This work was supported by the Nordic Cancer Union (NCU; S-01/07). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received January 4, 2011; revised June 1, 2011; accepted June 2, 2011; published OnlineFirst June 8, References 1. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006;12 Suppl 1:S Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in Results and commentary. Eur J Cancer 2009;45: Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., editors. New malignancies among cancer survivors: SEER Cancer Registries, Bethesda, MD: National Cancer Institute; p Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008;26: Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, Lin JT, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 2008;17: Evans HS, Lewis CM, Robinson D, Bell C, Møller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 2001;84: Rubino C, de Vathaire F, Diallo I, Shamsaldin A, L^e MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000;61: Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;118: Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007;106: Teppo L, Pukkala E, Saxen E. Multiple cancer an epidemiologic exercise in Finland. J Natl Cancer Inst 1985;75: Andersson M, Jensen MB, Engholm G, Henrik SH. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer Cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during Acta Oncol 2008;47: Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997;8: Buiatti E, Crocetti E, Acciai S, Gafa L, Falcini F, Milandri C, et al. Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997;33: Murakami H, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan a population-based cohort study. Jpn J Clin Oncol 1987;17: Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, Natl Cancer Inst Monogr 1985;68: Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009;4:e Sundhedsstyrelsen. Cancerregisteret København pdf. 18. Storm H, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry. Dan Med Bull 1997;44: Pukkala E. Finland cancer registration. In: Pukkala E, S oderman B, Okeanov A, Storm HH, Rahu M, Hakulinen T, et al., editors. Cancer atlas of Northern Europe. Helsinki, Finland: Cancer Society of Finland Publication 62; p Cancer Registry of Norway. Cancer in Norway Oslo: Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer 2003;4: Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361: Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10: Marshall JR, Freudenheim J. Alcohol. 3rd ed. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York: Oxford University Press; p World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; Hsing AW, Rashid A, Devesa SS, Fraumeni JF Jr. Biliary tract cancer 3rd ed. In: Schottenfeld D, Fraumeni JF Jr editors. Cancer epidemiology and prevention. New York: Oxford University Press; p Lindor NM, Lindor CJ, Greene MH. Hereditary neoplastic syndromes. 3rd ed. In: Schottenfeld D, Fraumeni JF Jr editors. Cancer epidemiology and prevention New York: Oxford University Press; p Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326: Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern? Cancer 2004;101: Cancer Epidemiol Biomarkers Prev; 20(8) August
9 Mellemkjær et al. 30. Berrington de GA, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102: Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326: Stovall M, Smith SA, Langholz BM, Boice JD Jr, Shore RE, Andersson M, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2008;72: Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004;111: Cancer Epidemiol Biomarkers Prev; 20(8) August 2011 Cancer Epidemiology, Biomarkers & Prevention
10 Risk of Primary Non Breast Cancer After Female Breast Cancer by Age at Diagnosis Lene Mellemkjær, Jane Christensen, Kirsten Frederiksen, et al. Cancer Epidemiol Biomarkers Prev 2011;20: Published OnlineFirst June 8, Updated version Access the most recent version of this article at: doi: / epi Cited articles Citing articles This article cites 25 articles, 2 of which you can access for free at: This article has been cited by 3 HighWire-hosted articles. Access the articles at: alerts Sign up to receive free -alerts related to this article or journal. Reprints and Subscriptions Permissions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. To request permission to re-use all or part of this article, use this link Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
Metachronous Double Primary Cancer after Treatment of Breast Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(1):64-71 Original Article http://dx.doi.org/10.4143/crt.2013.215 Open Access Metachronous Double Primary Cancer after Treatment of Breast Cancer
More informationEstimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationPrediction of Cancer Incidence and Mortality in Korea, 2018
pissn 1598-2998, eissn 256 Cancer Res Treat. 218;5(2):317-323 Special Article https://doi.org/1.4143/crt.218.142 Open Access Prediction of Cancer Incidence and Mortality in Korea, 218 Kyu-Won Jung, MS
More informationCancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationCancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
More informationProportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries
Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries Amy Berrington de Gonzalez, Rochelle E Curtis, Stephen F Kry, Ethel Gilbert,
More informationCancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
More informationCancer survival in Hong Kong SAR, China,
Chapter 5 Cancer survival in Hong Kong SAR, China, 1996 2001 Law SC and Mang OW Abstract The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods.
More informationEpidemiology MATERIALS AND METHODS
British Journal of Cancer (2006) 95, 1291 1295 All rights reserved 0007 0920/06 $30.00 www.bjcancer.com Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second
More informationPrediction of Cancer Incidence and Mortality in Korea, 2013
pissn 1598-2998, eissn 256 Cancer Res Treat. 213;45(1):15-21 Special Article http://dx.doi.org/1.4143/crt.213.45.1.15 Open Access Prediction of Cancer Incidence and Mortality in Korea, 213 Kyu-Won Jung,
More informationRisk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study
ONCOLOGY LETTERS 2: 963-973, 2011 Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study YUMI KAMIGAKI 1 and KOJI KAWAKAMI 2 1 Department of Biostatistics,
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Title: Multiple Subsequent Neoplasms Working Group and Investigators: Childhood Cancer Survivor Study Analysis Concept Proposal This proposed publication will be within the Second Malignancy Working Group
More informationSecond Cancers Among Survivors of Cervical Cancer: Evaluation of Long-Term Risk
ARTICLE Second Cancers Among 104 760 Survivors of Cervical Cancer: Evaluation of LongTerm Risk Anil K. Chaturvedi, Eric A. Engels, Ethel S. Gilbert, Bingshu E. Chen, Hans Storm, Charles F. Lynch, Per Hall,
More informationThe validity of the mortality to incidence ratio as a proxy for site-specific cancer survival
European Journal of Public Health, Vol. 21, No. 5, 573 577 ß The Author 2010. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved. doi:10.1093/eurpub/ckq120
More informationCancer survival in Seoul, Republic of Korea,
Cancer survival in Seoul, Republic of Korea, 1993 1997 Ahn YO and Shin MH Abstract The Seoul cancer registry was established in 1991. Cancer is a notifiable disease, and registration of cases is done by
More informationANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
More informationPredictions of cancer incidence in Poland in 2019
Cent. Eur. J. Med. 8(2) 2013 185-191 DOI: 10.2478/s11536-012-0103-z Central European Journal of Medicine Predictions of cancer incidence in Poland in 2019 Research Article Piotr Wojtyś* 1, Dariusz Godlewski
More informationWLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
More informationWLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274
More informationBenign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients
American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
More information*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
More informationExtract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study
EUROCARE-5 on-line database Data and methods Extract from Cancer survival in Europe 1999 2007 by country and age: results of EUROCARE-5 a population-based study De Angelis R, Sant M, Coleman MP, Francisci
More informationAnnual report on status of cancer in China, 2010
Original Article Annual report on status of cancer in China, 2010 Wanqing Chen, Rongshou Zheng, Siwei Zhang, Ping Zhao, Hongmei Zeng, Xiaonong Zou, Jie He National Office for Cancer Prevention and Control,
More informationLong-term survival of cancer patients in Germany achieved by the beginning of the third millenium
Original article Annals of Oncology 16: 981 986, 2005 doi:10.1093/annonc/mdi186 Published online 22 April 2005 Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium
More informationFAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN
Int. J. Cancer: 94, 444 448 (2001) 2001 Wiley-Liss, Inc. FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN Kari HEMMINKI* and Xinjun LI Department of Biosciences
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationCancer survival in Busan, Republic of Korea,
Cancer survival in Busan, Republic of Korea, 1996 2001 Shin HR, Lee DH, Lee SY, Lee JT, Park HK, Rha SH, Whang IK, Jung KW, Won YJ and Kong HJ Abstract The Busan cancer registry was established in 1996;
More informationDo morphology and stage explain the inferior lung cancer survival in Denmark?
Eur Respir J 1999; 13: 430±435 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Do morphology and stage explain the inferior lung cancer
More informationPeriod estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision
Journal of Clinical Epidemiology 59 (2006) 570 575 ORIGINAL ARTICLES Period estimates of cancer patient survival are more up-to-date than estimates even at comparable levels of precision Hermann Brenner
More informationTrends in cancer incidence in South East England Henrik Møller and all staff at the Thames Cancer Registry, King s College London
Trends in cancer incidence in South East England 1960-2009 Henrik Møller and all staff at the Thames Cancer Registry, King s College London 1 2 3 Analysts Vicki Coupland Ruth Jack Margreet Lüchtenborg
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
More informationTrends in Cancer Survival in Scotland
Scottish Cancer Intelligence Unit Trends in Cancer Survival in Scotland - Trends in survival are presented for the half million adult cancer patients diagnosed in Scotland between and. The Results show,
More informationCancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2012;44(1):11-24 Special Article http://dx.doi.org/10.4143/crt.2012.44.1.11 Open Access Cancer Statistics in Korea: Incidence, Mortality, Survival, and
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2011-2015) AVERAGE NUMBER OF DEATHS PER YEAR (2011-2015) Male Female Both sexes Male Female Both sexes 4,557 4,516 9,073 1 2,196 1,984 4,180
More informationAPPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
More informationCancer survival in Shanghai, China,
Cancer survival in Shanghai, China, 1992 1995 Xiang YB, Jin F and Gao YT Abstract The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely
More informationCancer in Utah: An Overview of Cancer Incidence and Mortality from
Cancer in Utah: An Overview of Cancer Incidence and Mortality from 1973-2010 A publication of the Utah Cancer Registry January 2014 Prepared by: C. Janna Harrell, MS Senior Research Analyst Kimberly A.
More informationRESEARCH ARTICLE. Cancer Prevalence in Aichi, Japan for 2012: Estimates Based on Incidence and Survival Data from Population- Based Cancer Registry
DOI:10.22034/APJCP.2017.18.8.2151 Estimates of Cancer Prevalence in Aichi RESEARCH ARTICLE Cancer Prevalence in Aichi, Japan for 2012: Estimates Based on Incidence and Survival Data from Population- Based
More informationRESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry
DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko
More informationSTUDY. Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin
Subsequent Cancers After In Situ and Invasive Squamous Cell Carcinoma of the Skin Kari Hemminki, MD, PhD; Chuanhui Dong, MD, PhD STUDY Objectives: To compare cancer risks after in situ and invasive squamous
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland
More informationCancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
pissn 1598-2998 eissn 2005-9256 Cancer Res Treat. 2011;43(1):1-11 Special Article DOI 10.4143/crt.2011.43.1.1 Open Access Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
More informationDRAFT. No. of cases/ deaths. categories. Number of X-ray exposures (for UK & Ireland only ever vs never)
Table 2.1. Cohort studies of X-ray and Andrieu et al. (2006) Europe & Canada Carr et al. (2002) US cohort X- rays for treatment of peptic ulcers 1601 female BRCA1 + BRCA2 carriers, aged 18+; disease ascertainment
More informationSurvival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period
Acta Obstetricia et Gynecologica. 2008; 87: 13531360 ORIGINAL ARTICLE Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period 1978 2002
More informationCancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
More informationKey Words. Cancer statistics Incidence Lifetime risk Multiple primaries Survival SEER
The Oncologist Epidemiology and Population Studies: SEER Series Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program MATTHEW
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationTrends in Lung Cancer Incidence by Histological Type in Osaka, Japan
Original Article Japanese Journal of Clinical Oncology Advance Access published August 9, 2008 Jpn J Clin Oncol 2008 doi:10.1093/jjco/hyn072 Trends in Lung Cancer Incidence by Histological Type in Osaka,
More informationSupplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
More informationDownloaded from:
Coleman, MP; Quaresma, M; Butler, J; Rachet, B (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK Reply. Lancet, 377 (9772). pp. 1149-1150. ISSN 0140-6736 Downloaded from:
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationSpecial issue: NORDCAN Cancer data from the Nordic countries
Special issue: NORDCAN Cancer data from the Nordic countries Editor: Siri Larønningen Writing group: Siri Larønningen, Inger Kristin Larsen, Bjørn Møller, Gerda Engholm 1, Hans H. Storm 1 and Tom Børge
More informationOverview of Hong Kong Cancer Statistics of 2015
Overview of Hong Kong Cancer Statistics of 2015 This report summarizes the key cancer statistics of Hong Kong for the year of 2015, which is now available on the website of Hong Kong Cancer Registry. Cancer
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationAnnual report on status of cancer in China, 2011
Original Article Annual report on status of cancer in China, 2011 Wanqing Chen, Rongshou Zheng, Hongmei Zeng, Siwei Zhang, Jie He National Office for Cancer Prevention and Control, National Cancer Center,
More informationMethodological choices affect cancer incidence rates: a cohort study
Brooke et al. Population Health Metrics (2017) 15:2 DOI 10.1186/s12963-017-0120-x RESEARCH Open Access Methodological choices affect cancer incidence rates: a cohort study Hannah L. Brooke *, Mats Talbäck,
More informationCancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 214;46(2):19-123 Special Article http://dx.doi.org/1.4143/crt.214.46.2.19 Open Access Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationCancer risks in thyroid cancer patients
Br. J. Cancer (1991), 64, 159-163 'PI Macmillan Press Ltd., 1991 Br. J. Cancer (1991), 64, 159 163 Macmillan Press Ltd., 1991 Cancer risks in thyroid cancer patients P. Hall', L.-E. Holm2, G. Lundell',
More informationCancer in Norway Cancer incidence, mortality, survival and prevalence in Norway
Cancer in Norway 7 Cancer incidence, mortality, survival and prevalence in Norway Special issue: Long-term cancer survival: patterns and trends in Norway 96-7 Cancer in Norway 7 Editor-in-chief: Freddie
More informationOverview of 2013 Hong Kong Cancer Statistics
Overview of 2013 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry (HKCaR) is a population-based cancer registry, collecting the basic demographic data, information
More informationCancer in Norway Cancer incidence, mortality, survival and prevalence in Norway
Cancer in Norway 2007 Cancer incidence, mortality, survival and prevalence in Norway Special issue: Long-term cancer survival: patterns and trends in Norway 1965-2007 Cancer in Norway 2007 Editor-in-chief:
More informationCANCER IN TASMANIA INCIDENCE AND MORTALITY 1996
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 Menzies Centre For Population Health Research Editors: Dace Shugg, Terence Dwyer and Leigh Blizzard Publication
More informationA Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files
A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files By Dr. Martin A. Whiteside Director, Office of Cancer
More informationChapter II: Overview
: Overview Chapter II: Overview This chapter provides an overview of the status of cancer in Minnesota, using cases reported to the Minnesota Cancer Surveillance System (MCSS) and deaths reported to the
More informationHazelinks - Cancer incidence analysis (First data extraction)
Hazelinks - Cancer incidence analysis (First data extraction) Authors Prof Malcolm Sim Ms Christina Dimitriadis Dr Caroline Gao Mr Anthony Del Monaco 1 1 Contents Abbreviations... 3 Executive Summary...
More informationTruman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 338 A PRIL 23, 1998 NUMBER 1 THE RISK OF A DIAGNOSIS OF CANCER AFTER PRIMARY DEEP VENOUS THROMBOSIS OR PULMONARY
More informationPost-diagnosis NSAID use and risk of contralateral breast cancer
Post-diagnosis NSAID use and risk of contralateral breast cancer a Danish nationwide cohort study Annet Bens 1, Søren Friis 1,2, Deidre Cronin-Fenton 3, Christian Dehlendorff 1, Maj-Britt Jensen 4, Bent
More informationAmerican Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
More informationTrends in Irish cancer incidence with predictions to 2020
Trends in Irish cancer incidence 1994-22 with predictions to 22 Trends in Irish cancer incidence 1994-22 with projections to 22 National Cancer Registry June 26 1 Acknowledgements. I would like to thank
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationAppendix 1 (as supplied by the authors): Supplementary data
Appendix 1 (as supplied by the authors): Supplementary data I. Cancer prevalence in Canada We obtained 10 year person based cancer prevalence rates for all of Canada for some years of our study period
More informationA Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY
More informationBleeding symptoms and subsequent risk of gynecological and other cancers
Acta Obstet Gynecol Scand 1998; 77: 564 569 Copyright C Acta Obstet Gynecol Scand 1998 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationCancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer
Cancer in Ontario 1 in 2 Ontarians will develop cancer in their lifetime 1 in 4 Ontarians will die from cancer 14 ONTARIO CANCER STATISTICS 2016 1 Cancer in Ontario An overview Cancer is a group of more
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Cancer incidence and mortality among members of the Danish resistance movement deported to German concentration camps: 65-Year follow-up Maja Halgren Olsen 1, Henrik
More informationSurvival Rates of Childhood Cancer Patients in Osaka, Japan
Jpn J Clin Oncol 2004;34(1)50 54 Epidemiology Note Survival Rates of Childhood Cancer Patients in Osaka, Japan Wakiko Ajiki, Hideaki Tsukuma and Akira Oshima Department of Cancer Control and Statistics,
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationNationwide Cancer Incidence in Korea,
Cancer Res Treat. 2009;41(3):122-131 DOI 10.4143/crt.2009.41.3.122 Special Article Nationwide Cancer Incidence in Korea, 2003 2005 Young-Joo Won, Ph.D. 1 Joohon Sung, M.D. 1,2 Kyu-Won Jung, M.S. 1 Hyun-Joo
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationCancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018
Cancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018 Tim Cowan, MSPH Director, Data Reporting and Evaluation Center for Health Improvement MaineHealth All Cancer Mortality
More informationCancer Statistics in Korea: Incidence, Mortality and Survival in
SPECIAL ARTICLE Oncology & Hematology DOI: 1.3346/jkms.21.25.8.1113 J Korean Med Sci 21; 25: 1113-1121 Cancer Statistics in Korea: Incidence, Mortality and Survival in 26-27 Kyu-Won Jung 1, Sohee Park
More informationCancer Statistics in Korea: Incidence, Mortality and Survival in 2005
J Korean Med Sci 29; 24: 995-13 ISSN 111-8934 DOI: 1.3346/jkms.29.24.6.995 Copyright The Korean Academy of Medical Sciences SPECIAL ARTICLE Cancer Statistics in Korea: Incidence, Mortality and Survival
More informationAll Discovered Death Outcome Detail (Form 124/120)
This file includes all reported deaths regardless of consent. ID WHI Common ID Col#1 DEATHALL All Discovered Death Col#2 Any report of death, regardless of consent status. 0 No 106,931 66.1 1 Yes 54,877
More informationCancer in Central and South America BOLIVIA
Cancer in Central and South America BOLIVIA This country profile for the Cancer in Central and South America project provides, for each participating cancer registry tables and graphics showing numbers
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More informationCancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationCancer in Norway Cancer incidence, mortality, survival and prevalence in Norway
Cancer in Norway 217 Cancer incidence, mortality, survival and prevalence in Norway Cancer in Norway 217 Cancer in Norway 217 Editor-in-chief: Inger Kristin Larsen Editorial team: IK Larsen, B Møller,
More informationAre Patients with Skin Cancer at Lower Risk of Developing Colorectal or Breast Cancer?
American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationSex Distribution of Solid Malignant Tumours in Basrah Retrospective Study
Bahrain Medical Bulletin, Vol. 26, No. 3, September 2004 Sex Distribution of Solid Malignant Tumours in Basrah Retrospective Study Mohammed K Al-Wiswasy, FRCPath* Rafeef A Al-Saddi, FICMS (Path)* Objective:
More information